Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
Xconomy
SEPTEMBER 18, 2020
This drug class has seen a lift in recent years. Some of those analysts think Gilead might have overpaid but the company says there were competing offers. The drug, sacitizumab govitecan (Trodelvy), is what’s called an antibody drug conjugate (ADC). Four years ago, there were just three FDA-approved ADCs. The FDA has approved.
67 
Let's personalize your content